BIOGEN IDEC INC | 179,05 Euro | -1,25 -0,69 % | |
| WKN: 789617 ISIN: US09062X1037 Ticker-Symbol: IDP | Frankfurt | 24.05.13 | 17:17 Uhr |
Branche BiotechnologieAktienmarkt NASDAQ-100S&P 500 NASDAQ Biotech |
|
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 24.05. | The loyalty behind Biogen's Tysabri drug | 9 | bizjournals | |
| 23.05. | Biogen Submits Plegridy BLA | 4 | Zacks | |
| 23.05. | Biogen Idec taps Harvard professor as new CSO | 2 | bizjournals | |
| 23.05. | Biogen Idec ernennt Spyros Artavanis-Tsakonas zum Chief Scientific Officer | 75 | Business Wire | |
| – Einstellung von renommiertem Wissenschaftler beweist Engagement für dynamische und innovative wissenschaftliche Forschung – Biogen Idec (NASDAQ:BIIB) hat heute bekannt gegeben,... Mehr lesen zu: Biogen Idec ernennt Spyros Artavanis-Tsakonas zum Chief Scientific Officer | ||||
| 23.05. | Biogen Idec Appoints Spyros Artavanis-Tsakonas Chief Scientific Officer | 32 | Business Wire | |
| – Addition of Renowned Scientist Underscores Commitment to Vibrant and Innovative Scientific Research – Biogen Idec (NASDAQ:BIIB) today announced that Spyros Artavanis-Tsakonas, ... Mehr lesen zu: Biogen Idec Appoints Spyros Artavanis-Tsakonas Chief Scientific Officer | ||||
| 23.05. | Biogen Idec seeks FDA approval for Plegridy in multiple sclerosis therapy | 2 | Pharma Bus Review | |
| 22.05. | Biogen MS drug No. 4 could be manufactured in RTP | 9 | bizjournals | |
| 22.05. | Biogen seeks FDA approval for fourth MS drug | 5 | bizjournals | |
| 22.05. | Another Multiple Sclerosis Winner for Biogen | 26 | Motley Fool | |
| 21.05. | Biogen submits new MS drug for FDA approval | 6 | Yahoo-USA | |
| 21.05. | Biogen Idec seeks approval for fourth MS drug | 6 | bizjournals | |
| 21.05. | Bullish Moving Average Cross by Biogen Idec | 4 | SmarTrend | |
| 21.05. | Biogen Idec Submits BLA to FDA for Approval of PLEGRIDY for Multiple Sclerosis | 3 | Benzinga.com | |
| 21.05. | Biogen Idec Submits BLA To FDA For Approval Of Plegridy In Multiple Sclerosis | 54 | AFX News | |
| WESTON (dpa-AFX) - Biogen Idec (BIIB) announced that it has submitted a
Biologics License Application or BLA to the U.S. Food and Drug Administration or
FDA for approval of Plegridy (peginterferon... Mehr lesen zu: Biogen Idec Submits BLA To FDA For Approval Of Plegridy In Multiple Sclerosis | ||||
| 21.05. | Biogen Idec Submits Application to FDA for Approval of PLEGRIDY™ (Peginterferon Beta-1a) in Multiple Sclerosis | 46 | Business Wire | |
| — EMA Submission Planned in the Coming Weeks — Today Biogen Idec (NASDAQ: BIIB) announced it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration... Mehr lesen zu: Biogen Idec Submits Application to FDA for Approval of PLEGRIDY™ (Peginterferon Beta-1a) in Multiple Sclerosis | ||||
| 21.05. | Biogen Idec reicht Zulassungsantrag für PLEGRIDY™ (Peginterferon Beta-1a) zur Behandlung der multiplen Sklerose bei der FDA ein | 63 | Business Wire | |
| — EMA-Antrag für die kommenden Wochen geplant Wie Biogen Idec (NASDAQ: BIIB) heute mitteilte, wurde bei der US-amerikanischen Arzneimittelbehörde (FDA) ein Antrag (Biologics License... Mehr lesen zu: Biogen Idec reicht Zulassungsantrag für PLEGRIDY™ (Peginterferon Beta-1a) zur Behandlung der multiplen Sklerose bei der FDA ein | ||||
| 20.05. | Biogen's Hemophilia BLA Accepted | 15 | Zacks | |
| 17.05. | Genmab A/S: Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case | 95 | GlobeNewswire | |
| Company Announcement
-- Genentech and Biogen Idec have filed for re-hearing in the United States
Copenhagen, Denmark; May 17, 2013 - Genmab A/S (OMX: GEN) announced today that
Genentech and Biogen... Mehr lesen zu: Genmab A/S: Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case | ||||
| 16.05. | Biogen Idec Foundation gift to introduce youth to genetics programming | 5 | bizjournals | |
| 13.05. | Biogen says FDA starts hemophilia drug review | 30 | Yahoo-USA | |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| AMGEN | 82,00 | +0,79 % | Amgen to Present at the Deutsche Bank 38th Annual Healthcare Conference |
| QIAGEN | 14,66 | +1,14 % | QIAGEN Downgraded to Strong Sell |
| BB BIOTECH | 94,51 | -0,55 % | XFRA H MISTRADE ANTRAG IN ISIN CH0038389992 WURDE STATTGEGEBEN |
| MORPHOSYS | 34,64 | -0,17 % | MorphoSys AG: Veröffentlichung gem. § 26 Abs.1 WpHG mit dem Ziel der europaweiten Verbreitung |
| MEDIGENE | 0,93 | +4,61 % | Medigene: Rating wird erneuert |
